The Max Foundation is excited to include Graciela Mabel Woloj Rothstein and Mikkel Z. Oestergaard, PhD as the newest Strategic Innovation Advisory Board member.
Graciela Mabel Woloj Rothstein is an experienced leader with a demonstrated history of working within the pharmaceuticals industry. Rothstein brings her expertise in the fields of Oncology, Good Clinical Practice (GCP), Pharmacovigilance, Clinical Trial Management System (CTMS), and Biotechnology.
Dr. Mikkel Z Oestergaard is Director of Health Technology Assessment (HTA) Statistics within the Department of Biostatistics and Research Decision Sciences at Merck/MSD and is based in Zurich, Switzerland. He has 16 years of professional experience and more than 40 peer-reviewed scientific publications in the areas of clinical drug development, health statistics and evidence-generation for public health impact. Dr. Oestergaard previously worked at the World Health Organization (WHO) headquarter before subsequently moving to the pharmaceutical industry. At the WHO he focused on evaluation of the global burden of disease, and co-founded WHO’s Global Initiative on Genomics for Public Health.
We are eager to learn from Rothstein and Oestergaard’s knowledge and experience in the pharmaceutical industry, in order to bring more access to treatment for patients worldwide. Join us in welcoming Graciela Mabel Woloj Rothstein and Mikkel Z. Oestergaard, PhD to our advisory board!
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
By Pat Garcia-Gonzalez Birthdays are a time to take stock on our life. This birthday, I feel unsettled, questioning if I am doing everything I can. A few weeks ago, I sat in a small consult room. A gentleman walked wearing gray slacks, a white buttoned shirt, and suit coat, he must have been in….
The Max Foundation is pleased to announce the hiring of Wilma Comenat as Vice President of Development of The Max Foundation. Wilma has more than 20 years of experience in the nonprofit sector leading development teams and driving major donor fundraising initiatives. Her previous roles include the Associate Executive Director of JDRF Greater Northwest, Regional Director of Lupus Foundation of America, Inc.’s Pacific Northwest region, and Deputy Executive Director of The Leukemia & Lymphoma Society.
Armenia and Nepal are the first of 29 countries to receive CLL treatment SEATTLE & BASEL & BEIJING & CAMBRIDGE, Mass. – March 13, 2024 — The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global oncology company, and….
